- Home
- OGS vs CRSP Comparison
OGS vs CRSP Comparison
Compare OGS & CRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OGS
- CRSP
- Stock Information
- Founded
- OGS 1906
- CRSP 2013
- Country
- OGS United States
- CRSP Switzerland
- Employees
- OGS N/A
- CRSP N/A
- Industry
- OGS Oil/Gas Transmission
- CRSP Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- OGS Utilities
- CRSP Health Care
- Exchange
- OGS Nasdaq
- CRSP Nasdaq
- Market Cap
- OGS 4.2B
- CRSP 4.3B
- IPO Year
- OGS N/A
- CRSP 2016
- Fundamental
- Price
- OGS $70.71
- CRSP $44.11
- Analyst Decision
- OGS Hold
- CRSP Buy
- Analyst Count
- OGS 6
- CRSP 18
- Target Price
- OGS $70.92
- CRSP $76.60
- AVG Volume (30 Days)
- OGS 385.5K
- CRSP 1.8M
- Earning Date
- OGS 11-04-2024
- CRSP 11-05-2024
- Dividend Yield
- OGS 3.74%
- CRSP N/A
- EPS Growth
- OGS N/A
- CRSP N/A
- EPS
- OGS 3.82
- CRSP N/A
- Revenue
- OGS $2,058,772,000.00
- CRSP $202,829,000.00
- Revenue This Year
- OGS $3.33
- CRSP N/A
- Revenue Next Year
- OGS $7.51
- CRSP $758.18
- P/E Ratio
- OGS $18.46
- CRSP N/A
- Revenue Growth
- OGS N/A
- CRSP 19.31
- 52 Week Low
- OGS $57.74
- CRSP $42.86
- 52 Week High
- OGS $78.89
- CRSP $91.10
- Technical
- Relative Strength Index (RSI)
- OGS 34.94
- CRSP 39.11
- Support Level
- OGS $69.85
- CRSP $43.40
- Resistance Level
- OGS $71.17
- CRSP $53.97
- Average True Range (ATR)
- OGS 1.37
- CRSP 2.37
- MACD
- OGS -0.57
- CRSP -0.78
- Stochastic Oscillator
- OGS 9.68
- CRSP 9.53
About OGS ONE Gas Inc.
ONE Gas Inc is a regulated natural gas utility company. It is involved in the distribution and sale of natural gas to residential, commercial, industrial, and transportation consumers through its network of pipelines and service lines. Almost all of the company's revenue is derived from natural gas sales in the states of Oklahoma, Kansas, and Texas. The company controls considerable market shares in Oklahoma and Kansas.
About CRSP CRISPR Therapeutics AG
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.